Biocom

Accelerating Life Science

[Biocom @Biocom]

Nominations are now open for the 11th annual Biocom Catalyst Awards, recognizing exceptional life science professionals under 40 who are driving innovation, leadership and impact across our industry.

Nominate a standout leader: https://t.co/FHQQ37T8U4

[Biocom @Biocom]

In this month's Regulatory & Reimbursement Newsletter: Biocom submitted comments in response to the FDA’s draft guidance on the use of new approach methodologies in drug development, Kyle Diamantas will serve as acting FDA commissioner following Dr. Makary’s resignation, Michael Davis has been appointed acting director of CDER and more. Read it here: https://t.co/3qYwsRJYpR

[Biocom @Biocom]

It's #NewMemberMonday!
🔬 Ablytx develops drugs that degrade disease-driving proteins on cell surfaces.
🌱 Caffree uses enzymes to convert caffeine into theobromine while preserving flavor and sustainability.
🫀 @Cyclarity Therapeutics develops therapies that target toxic cholesterol to reverse age-related diseases.
💻 Engine Biosciences combines AI and high-throughput biology to accelerate drug discovery and cellular reprogramming.
🩺 @REVClinicalCRO partners with emerging and mid‑size biopharma companies to deliver fast, flexible and capital‑efficient global clinical trials.
🧬 Vivere Oncotherapies engineers next generation gene therapy delivery systems to unlock immunotherapy for hard-to-treat solid tumors.

[Biocom @Biocom]

Catch the most recent Group Purchasing Newsletter to learn more about @centrexIT's new website, @FedEx's AI-powered partnership with ServiceNow, @SharpBusinessUS's zero-waste-toner solution, and @ThermoFisher's new integrated therapy manufacturing platform, partner news and more. Read the full edition: https://t.co/okJ4W7EQEo

[Biocom @Biocom]

What if the biggest breakthrough in drug discovery isn't a new molecule, but a better way to understand human biology?

In our latest Member Spotlight, @GATCHealth CTO Jayson Uffens discusses using AI, multi-omics and human-derived data to model disease and reduce development risk before therapies reach the lab. Read more: https://t.co/Xllq4d3Lq4

[Biocom @Biocom]

This week in the Bay Area life sciences:
🧠 Alamar Biosciences unveiled GPND-AI NULSIA, a 15-protein AI classifier for diagnosis and co-pathology profiling across neurodegenerative diseases.
📊BioMarin shared a new update on their Phase 3 trial for BMN 401, evaluating treatments for children ages 1–12 with ENPP1 deficiency.
❤️Cyclarity presented data demonstrating the excretion of oxidized cholesterol at the American Heart Association (AHA) Vascular Discovery Scientific Session.
Subscribe to receive the next newsletter in your inbox: https://t.co/LLI4Wijs6c

[Biocom @Biocom]

Join our member @Hands_OnLLC for a live virtual course on AI in Life Sciences on June 18, covering emerging AI trends, real-world applications and practical business considerations across biopharma and medtech. Learn more: https://t.co/QmNaLONC6k

[Biocom @Biocom]

This week in San Diego life sciences:
🧠UCSD is now using machine learning along with wearable technology to personalize depression treatments.
🔬Biotheryx released data from their Phase 1 dose-escalation study of BTX-9341.
🧬Degron Therapeutics closed a $40 million Series A extension to support the clinical development of their molecular glue degrader.
💊Neurocrine Biosciences presented data highlighting the functional impact of mild tardive dyskinesia severity and improvement seen with INGREZZA (valbenazine) capsules.
Subscribe to receive the next newsletter in your inbox: https://t.co/xfUBQQVpsS

[Biocom @Biocom]

Biocom members @CDDVault and @EliLillyandCo announced a new agreement to integrate Lilly TuneLab into CDD Vault, expanding biotech access to AI/ML models designed to accelerate drug discovery and innovation. Learn more: https://t.co/XsqWNhQcBV

[Biocom @Biocom]

Each May, #ALSAwarenessMonth highlights the urgent need for continued progress in the fight against ALS. Organizations like @youralsnetwork, alongside innovators including @annexonbio, @acurastem and @BloomScience, are helping drive new momentum in ALS research and treatment innovation.

Continued investment in research, advocacy and collaboration will be critical to advancing more effective therapies, and ultimately, a cure. #EndALS

[Biocom @Biocom]

This week in Bay Area life sciences:
🧬 Addition Therapeutics shared preclinical proof‑of‑concept data at the ASGCT 29th Annual Meeting.
👁️ @BayerPharma announced plans to acquire Perfuse Therapeutics to strengthen its ophthalmology pipeline.
❤️ @Cytokinetics presented new MYOQORZO (aficamten) data at ESC Heart Failure 2026.
Subscribe to receive the next newsletter in your inbox: https://t.co/LLI4Wijs6c

[Biocom @Biocom]

A reminder to join us for an exclusive webinar with the Advanced Research Projects Agency for Health (ARPA-H) designed to help organizations better understand how to leverage partnership opportunities within ARPA-H programs.

Hear directly from Sam Gussman-Toh, lead program specialist for ARPA-H’s Small Business Program, as he shares insights into the agency’s research and funding programs in addition to how organizations can engage with ARPA-H.

This free-to-attend virtual event will be held May 28, 2026, from 12 p.m. – 1 p.m. PDT.

RSVP by May 27.

Learn more: https://t.co/OpqQxHe1qS

[Biocom @Biocom]

This week in San Diego life sciences: @Capricor filed a lawsuit against Nippon Shinyaku related to Duchenne drug pricing and launch issues; @aTyrNewsprovided a regulatory and clinical update for efzofitimod following an FDA Type C Meeting; @Inhibrx reported interim Phase 2 data for INBRX‑106. Subscribe: https://t.co/xfUBQQVpsS

[Biocom @Biocom]

In this month’s Policy & Advocacy Newsletter, we cover the California governor’s proposal for a permanent R&D credit limitation, President Trump’s released FY27 budget request, a signal to new funding opportunities in the Greater LA region and more. Read the full newsletter here: https://t.co/2rpOBGQiMM

[Biocom @Biocom]

Science moves fast. Today is a reminder to slow down just enough to enjoy the ride.

There is still time to stop by our @SANDAG Bike Anywhere Day pit stop and spend part of your morning with the Biocom team. Join us at Nourish Eats at One Alexandria Square for a free coffee cart, snacks, and giveaways. Thanks to everyone who has already biked by!

[Biocom @Biocom]

What does it take to move ocular melanoma therapeutics from translational strategy to patient impact? Join our member @pharmaron for its next BioInnovate webinar, featuring Sandeep Kumar and Dr. Arun Singh discussing the evolving landscape of ocular melanoma therapeutics.

Register now: https://t.co/uWa3VMc3bl

[Biocom @Biocom]

It's #NewMemberMonday!
💉 @ImmuneBridge manufactures high quality, scalable cell therapies at ultralow cost.
💼 @KSProp develops best‑in‑class laboratory and advanced manufacturing real estate for science‑driven companies.
🤖 @TactusAI automates laboratory operations by pairing humanoid robots with intelligent lab orchestration software to maximize throughput.
✨ Antheia applies advanced biosynthesis to rapidly produce high-value drug ingredients at commercial scale.
💊 Noven Pharmaceuticals commercializes transdermal prescription therapies to improve patient care.
🫀 Vasa Therapeutics discovers novel therapeutics targeting the biological drivers of cardiovascular aging.

[Biocom @Biocom]

Biking to work this Thursday? Be sure to plan your pit stop at Nourish Eats on the corner of N Torrey Pines and Science Park to meet the Biocom team!

[SANDAG @SANDAG]

🚴🙌 T-minus one week until #SANDAG Bike Anywhere Day! Register for our free event on Thursday, May 21, and pedal to one of the 100+ pit stops between 6:30 and 9:30 a.m. to pick up a free t-shirt, while supplies last.
🔗 Register: https://t.co/8E7odkXpAc

#BikeAnywhereSD

[Biocom @Biocom]

Final call to participate in the 2026 Life Science Total Rewards Survey, powered by Marsh McLennan Agency in partnership with Biocom Institute.

This is your last chance to contribute to one of the life science industry’s premier compensation benchmarking resources. If you haven’t participated yet, there's still time. This survey takes approximately 60–75 minutes to complete, and participating organizations will receive a complimentary copy of the full report once the survey closes.

Complete the survey by May 22: https://t.co/fHmmrnosuF

Questions or access issues? Contact [email protected]

[Biocom @Biocom]

From curiosity-driven discovery to life-changing breakthroughs, scientific innovation continues to shape the future of medicine and society.

Join @ucsdbiosciences Dean Kit Pogliano and 2025 Nobel Laureate Fred Ramsdell on June 11 in San Diego or virtually for a Deep Look Public Speaker Series conversation on advancing biomedical research and strengthening public trust in science.

Learn more and register: https://t.co/19E4t16B9Z